Show simple item record

dc.contributor.authorMcMahon, LP
dc.contributor.authorCai, MX
dc.contributor.authorBaweja, S
dc.contributor.authorHolt, SG
dc.contributor.authorKent, AB
dc.contributor.authorPerkovic, V
dc.contributor.authorLeikis, MJ
dc.contributor.authorBecker, GJ
dc.date.accessioned2021-02-22T22:20:14Z
dc.date.available2021-02-22T22:20:14Z
dc.date.issued2012-06-15
dc.identifierpii: 1471-2369-13-40
dc.identifier.citationMcMahon, L. P., Cai, M. X., Baweja, S., Holt, S. G., Kent, A. B., Perkovic, V., Leikis, M. J. & Becker, G. J. (2012). Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study. BMC NEPHROLOGY, 13 (1), https://doi.org/10.1186/1471-2369-13-40.
dc.identifier.issn1471-2369
dc.identifier.urihttp://hdl.handle.net/11343/264743
dc.description.abstractBACKGROUND: Anaemia of chronic kidney disease increases the risk of death and adverse events, but can be managed using erythropoiesis stimulating agents (ESAs). However, recent evidence suggests that targeting a higher haemoglobin concentration ([Hb]) increases mortality risk, and both higher [Hb] targets and ESA doses have been implicated. Nonetheless, a causative role has not been demonstrated, and this potential relationship requires further appraisal in such a complex patient group. METHODS: The relationship between the haematopoietic response to ESAs and patient survival in 302 stable, prevalent dialysis patients was explored in a prospective, single-centre study. Clinical and laboratory parameters influencing mortality and ESA resistance were analysed. Patients were stratified into 5 groups, according to their [Hb] and ESA dosage, and were followed for 2 years. RESULTS: Little difference in co-morbidities between groups was identified. 73 patients died and 36 were transplanted. Initial analysis suggested a direct relationship between mortality and ESA dosage. However, Cox proportional hazards multivariate analysis demonstrated mortality risk was associated only with age (adjusted HR per year: 1.061, 95% CI 1.031-1.092), dialysis duration (adjusted HR: 1.010, 95% CI 1.004-1.016), peripheral vascular disease (adjusted HR: 1.967, 95% CI 1.083-3.576) and CRP (adjusted HR: 1.024, 95% CI 1.011-1.039). Mortality was increased in patients poorly responsive to ESAs (55.5%). CONCLUSION: ESA dose does not appear to contribute substantially to mortality risk in dialysis patients. Instead, age and co-morbidities appear to be the critical determinants. A poor response to ESAs is a marker of overall poor health status.
dc.languageEnglish
dc.publisherBMC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleMortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study
dc.typeJournal Article
dc.identifier.doi10.1186/1471-2369-13-40
melbourne.affiliation.departmentClinical School (Royal Melbourne Hospital)
melbourne.affiliation.departmentMedicine (RMH)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleBMC Nephrology
melbourne.source.volume13
melbourne.source.issue1
dc.rights.licenseCC BY
melbourne.elementsid404737
melbourne.contributor.authorBECKER, GAVIN
melbourne.contributor.authorLEIKIS, MURRAY
melbourne.contributor.authorPERKOVIC, VLADO
melbourne.contributor.authorHolt, Stephen
melbourne.contributor.authorCai, Michael
dc.identifier.eissn1471-2369
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record